Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $263,958.75 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 10,125 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $26.07, for a total transaction of $263,958.75. Following the sale, the director directly owned 62,291 shares of the company’s stock, valued at $1,623,926.37. The trade was a 13.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The shares were sold at an average price of $27.25, for a total transaction of $301,058.00.
• On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The stock was sold at an average price of $26.23, for a total transaction of $1,633,892.93.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total transaction of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total transaction of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Price Performance

Shares of Immunome stock opened at $27.20 on Friday. The stock has a market cap of $3.09 billion, a P/E ratio of -10.75 and a beta of 2.08. The stock’s 50 day simple moving average is $22.20 and its 200-day simple moving average is $22.24. Immunome, Inc. has a 1-year low of $8.66 and a 1-year high of $28.62.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). As a group, research analysts expect that Immunome, Inc. will post -2.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Jupiter Topco LLC purchased a new position in Immunome in the second quarter worth approximately $973,000. Primecap Management Co. CA acquired a new stake in Immunome during the second quarter worth $97,081,000. Parkman Healthcare Partners LLC purchased a new stake in Immunome in the second quarter valued at $12,591,000. Legal & General Group Plc purchased a new stake in Immunome in the second quarter valued at $1,899,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Immunome in the 2nd quarter valued at $3,664,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IMNM. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Truist Financial boosted their price target on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a report on Saturday. Barclays started coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. Finally, Wedbush lifted their target price on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.64.

More Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Investors remain focused on the FDA’s acceptance of Immunome’s varegacestat NDA and an April 2027 PDUFA decision date. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program, providing potential catalysts for the stock. Immunome catalysts and Strong Buy analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a potential transition to profitability over the longer term, forecasting positive EPS of $0.40 in fiscal 2029 and $1.08 in fiscal 2030. These estimates support the longer-term investment case despite current losses.
• Neutral Sentiment: Director Isaac Barchas sold shares under a pre-arranged Rule 10b5-1 plan, including 98,712 shares from August 10–12 for roughly $2.6 million. The planned nature of the transactions makes them a less definitive signal about management’s current outlook, although the sales may weigh on sentiment. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss of $0.51. The earnings miss triggered a recent gap lower and highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome shares gap down after earnings miss
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term: Q3 2026 to $(0.65) from $(0.51), Q4 to $(0.68) from $(0.53), fiscal 2026 to $(2.45) from $(1.99), and fiscal 2027 to $(2.11) from $(1.72). The cuts suggest slower progress toward profitability, even though the firm retained its Buy rating.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.